All In Biotech

Investigational drug · Phase 2

Brogidirsen

Also called: NS-089, NCNP-02

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Duchenne Muscular Dystrophy, Exon 44, DMD.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

3

Any phase or sponsor naming "Brogidirsen"

First trial start

2021

Jun 23, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Brogidirsen", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Duchenne Muscular Dystrophy
  • Exon 44
  • DMD
  • Duchenne Muscular Dystrophy (DMD)

Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "Brogidirsen" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 6 on PubMed

Also in development for Duchenne Muscular Dystrophy

  • AOC 1044Phase 33 trials

    Avidity Biosciences, Inc. · DMD, Duchenne Muscular Dystrophy, Exon 44

  • DeramiocelCAP-1002, Allogeneic Cardiosphere-Derived CellsPhase 32 trials

    Capricor Inc. · Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic

  • SGT-003Phase 32 trials

    Solid Biosciences Inc. · Duchenne Muscular Dystrophy, Advanced Solid Tumor

  • SevasemtenPhase 24 trials

    Edgewise Therapeutics, Inc. · Becker Muscular Dystrophy, Duchenne Muscular Dystrophy

  • BMN 351Phase 22 trials

    BioMarin · Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy

  • SAT-3247Phase 22 trials

    Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD

  • WVE-N531Phase 22 trials

    Wave Life Sciences USA, Inc. · Duchenne Muscular Dystrophy

  • NS-050NCNP-03Phase 21 trial

    NS Pharma, Inc. · Duchenne Muscular Dystrophy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.